Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.43 |
| ▸ | AXL | P30530 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.32 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10133959 | 0.88 | MET (0.54) | METAXLKDRAURKB | |
| SCHEMBL14949032 | 0.88 | MET (0.41) | METAXLKDRAURKBCSF1R | |
| SCHEMBL10133775 | 0.78 | MET (0.50) | METAXLKDRAURKB | |
| SCHEMBL18040371 | 0.77 | MET (0.47) | METAXLKDR | |
| SCHEMBL10133801 | 0.77 | MET (0.46) | METAXLKDRAURKB | |
| SCHEMBL10134550 | 0.76 | MET (0.67) | METAXLKDR | |
| SCHEMBL371039 | 0.72 | MET (0.51) | METAXLKDR | |
| SCHEMBL368546 | 0.71 | MET (0.65) | METAXLKDR | |
| SCHEMBL18040363 | 0.68 | MET (0.49) | METAXLKDR | |
| SCHEMBL14937573 | 0.67 | TSHR (0.42) | METAXLSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242991-B2 | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-01-26 | — | — | US | disclosed |
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123286-A1 | Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors | MET, RET, ABL1 | MET 1/4885AXL 408/4885KDR 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.